AbbVie to Present at the Jefferies 2016 Healthcare Conference
Get Alerts ABBV Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.7%
EPS Growth %: +26.6%
Join SI Premium – FREE
NORTH CHICAGO, Ill., May 26, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Jefferies 2016 Healthcare Conference on Wednesday, June 8, 2016. Bill Chase, executive vice president and chief financial officer, will participate in a question and answer session at 7:30 a.m. Central time.
A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at www.abbvieinvestor.com. An archived edition of the session will be available later that day.
About AbbVieAbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/abbvie-to-present-at-the-jefferies-2016-healthcare-conference-300275307.html
SOURCE AbbVie
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity
- Celebrating America's Enduring Spirit of Freedom and Opportunity
- AbbVie's epcoritamab combo meets primary endpoint in lymphoma trial
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Jefferies & Co, TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share